Speaker Profile
PMWC PIONEER AWARD
Pioneered clinical tumor genomic profiling and precision oncology
M.D., Ph.D., Head of Global Product Development and Chief Medical Officer, Roche
Biography
Levi Garraway is a global leader in precision oncology, with a career spanning groundbreaking research, biotech innovation, and executive leadership in drug development.
At Roche, he oversees one of the industry’s most advanced pipelines. Under his leadership, Roche has deepened its use of genetic and molecular data to guide clinical understanding. Roche has also pioneered the use of real-world data and AI across the R&D continuum to guide discovery and development of new therapies.
Previously, Levi was on faculty at Dana-Farber Cancer Institute, Harvard Medical School and the Broad Institute, where his lab helped define early cancer mutation landscapes, identify therapeutic vulnerabilities, and characterize mechanisms of resistance to cancer therapies. During that time, Levi co-founded Foundation Medicine (now part of the Roche Group), a leading genomics-based cancer diagnostics company that has transformed precision oncology practice worldwide.
Levi has authored 200+ scientific publications. He serves on the board of trustees for the Dana-Farber Cancer Institute and advisory boards for MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center and the American Association for Cancer Research.
Talk
Future Breakthroughs in ImmunoOncology: New Targets, Modalities Combinations
Session Abstract – PMWC 2026 Silicon Valley
Track Chair: Ira Mellman, Medici Therapeutics
PMWC Award Ceremony
• Jedd D. Wolchok, Weill Cornell Medicine
• Suzanne Topalian, Johns Hopkins
• Levi Garraway, Roche
Targeting the Tumor Microenvironment (TME) in Practice: Biomarkers & Combos
• Chair: Ira Mellman, Medici Therapeutics
• Dmitry Gabrilovich, AstraZeneca
Immunotherapy with Personalized Cancer Vaccines: Who, When, How Fast?
• Chair: Suzanne Topalian, Johns Hopkins
• Tal Zaks, Orbimed
• Lelia Delamarre, Genentech
ADCs in the Checkpoint Era: Who Benefits, What to Combine, What to Avoid
• Chair: Shreya Badhrinarayanan, Pfizer
• S. Peter Kang, Daiichi Sankyo
Strategic IP Management in Cell and Gene Therapy: Navigating Legal and Practical Challenges
• Janet Xiao, Morrison & Foerster LLP
Checkpoint 2.0 in Practice: PD-1+VEGF Wins, Resistance Salvage & Biomarker Gates
• Chair: Jedd D. Wolchok, Weill Cornell Medicine
Future Breakthroughs in Immuno-Oncology: New Targets, Modalities & Biomarker Decision Gates
• Chair: Levi Garraway, Roche
